Does Belumosudil Interact with P Gp Or Bcrp Substrates?
CDI records a major classification for Belumosudil and P Gp Or Bcrp Substrates. The stored summary is: Belumosudil affects P-gp substrates for which minimal concentration changes may lead to serious toxicities. Avoid concomitant use where possible; if necessary, decrease substrate dosages. The mechanism involves belumosudil is a p-gp inhibitor. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Belumosudil is a P-gp inhibitor
What To Tell Your Doctor or Pharmacist
If you are taking Belumosudil and your doctor is considering prescribing P Gp Or Bcrp Substrates (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider